Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H17O3.Na |
| Molecular Weight | 208.2299 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC(C([O-])=O)C1(O)CCCCC1
InChI
InChIKey=ZIKJCAPMXXTMDD-UHFFFAOYSA-M
InChI=1S/C10H18O3.Na/c1-2-8(9(11)12)10(13)6-4-3-5-7-10;/h8,13H,2-7H2,1H3,(H,11,12);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H17O3 |
| Molecular Weight | 185.2402 |
| Charge | -1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Cyclobutyrol (CB) is a choleretic agent, which also inhibits biliary lipid secretion. Administration of cyclobutyrol reduced biliary concentration and output of cholesterol and phospholipid. This is due to an uncoupling of the secretion of cholesterol and phospholipids from that of bile acids. Biliary outputs of the canalicular membrane enzymes 5'-nucleotidase and alkaline phosphodiesterase I are depressed. The most likely effect of CB is exerted at the level of the canalicular membrane.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:50:59 GMT 2025
by
admin
on
Mon Mar 31 18:50:59 GMT 2025
|
| Record UNII |
9EA1G6PR44
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1130-23-0
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | |||
|
23695302
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | |||
|
m1096
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000084673
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | |||
|
236180
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB01523MIG
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | |||
|
DTXSID00920971
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | |||
|
9EA1G6PR44
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY | |||
|
214-458-6
Created by
admin on Mon Mar 31 18:50:59 GMT 2025 , Edited by admin on Mon Mar 31 18:50:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |